Breaking News

Cytovance Expands Keystone Expression System

March 10, 2016

Platform aims to address obstacles for researchers using E. coli

Cytovance Biologics, Inc. has expanded its Keystone Expression System to address obstacles for researchers using the Gram-negative bacterium, E. coli, related to cost of goods, scale-up challenges, or in-process control.

Cytovance Biologics has developed an E. coli expression platform using a toolbox approach to gene design, host construction, and screening evaluation. According to the company, partnering of DNA2.0's GeneGPS Codon Optimization with its Keystone Expression System creates an IP-free and robust method for developing an integrated manufacturing process that addresses challenges unique to each molecule and circumvents pitfalls that can arise in manufacturing.

"We have performed expression feasibility studies with eleven different products. The primary screening of each molecule was tested in 24 versions of E. coli within an 8-week time frame using an accurate and efficient work-flow," said April Stanley, Manager, Cell Line & Strain Development. Cytovance performed demonstration runs with some industrially relevant molecules. One such demonstration with hGH yielded 12g per liter in a platform high-cell density fermentation process.

"Cytovance does not charge a royalty for its expression system as is the case with many CMOs," said Ms. Stanley. "We charge a flat fee for the service. In 12 weeks, we provide our clients with 24 candidate strains accompanied by accurate fermentation manufacturability data. This data set is the starting point for future process development, which is a streamlined scope of work that focuses on robustness of the manufacturing process."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

    Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

    B.D. Naumann, P.J. Nigro, U. Bruen, L. Parola, D. Cragin and A. Schatz, Merck & Co., Inc. and Ashland, Inc.||May 5, 2016
    Health-based exposure limits are needed to support risk assessments

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.